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Background-—The NLR family, pyrin domain containing 3 (NLRP3) inflammasome is an interleukin (IL)-1b and IL-18 cytokine
processing complex that is activated in inflammatory conditions. The role of the NLRP3 inflammasome in the pathogenesis of
atherosclerosis and myocardial infarction is not fully understood.
Methods and Results-—Atherosclerotic plaques were analyzed for transcripts of the NLRP3 inflammasome, and for IL-1b release. The
Swedish First-ever myocardial Infarction study in Ac-county (FIA) cohort consisting of DNA from 555 myocardial infarction patients
and 1016 healthy individuals was used to determine the frequency of 4 single nucleotide polymorphisms (SNPs) from the downstream
regulatory region of NLRP3. Expression of NLRP3, Apoptosis-associated speck-like protein containing a CARD (ASC), caspase-1
(CASP1), IL1B, and IL18 mRNA was significantly increased in atherosclerotic plaques compared to normal arteries. The expression of
NLRP3 mRNA was significantly higher in plaques of symptomatic patients when compared to asymptomatic ones. CD68-positive
macrophages were observed in the same areas of atherosclerotic lesions as NLRP3 and ASC expression. Occasionally, expression of
NLRP3 and ASCwas also present in smoothmuscle cells. Cholesterol crystals and ATP induced IL-1b release from lipopolysaccharide-
primed human atherosclerotic lesion plaques. The minor alleles of the variants rs4266924, rs6672995, and rs10733113 were
associated with NLRP3 mRNA levels in peripheral blood mononuclear cells but not with the risk of myocardial infarction.
Conclusions-—Our results indicate a possible role of the NLRP3 inflammasome and its genetic variants in the pathogenesis of
atherosclerosis. ( J Am Heart Assoc. 2016;5:e003031 doi: 10.1161/JAHA.115.003031)
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A therosclerosis is a multifactorial, chronic inflammatorydisease that causes myocardial infarction (MI) and acute
ischemic stroke.1 Enhanced activation of inflammatory path-
ways and their bidirectional interaction with lipid pathology
and accumulation are hallmarks of atherosclerosis. Several
inflammatory cytokines are activated during this process,
including interleukin (IL)-1b and IL-18 that are overexpressed
in atherosclerotic lesions.2–5 The importance of IL-1b and
IL-18 in atherosclerosis is further supported by studies in
mice showing that IL-1b and IL-18 deficiency has been shown
to attenuate plaque development.6,7
Pro-IL-1b and pro-IL-18 are processed by caspase-1 to
their active form upon activation of inflammasomes, of which
the NLR family, pyrin domain containing (NLRP) 3 inflamma-
some is of particular importance.8 Caspase-1 is a key
constituent of this inflammasome together with NLRP3 and
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an adaptor protein termed Apoptosis-associated speck-like
protein containing a CARD (ASC).9 The release of IL-1b and
IL-18 requires 2 signals; signal 1 (eg, Toll-like receptor [TLR]4)
agonists and certain inflammatory cytokines such as tumor
necrosis factor that primes the inflammasome by enhancing
mRNA levels of NLRP3, IL-1b, and IL-18; and signal 2 that
results in the assembly of the NLRP3 inflammasome and
caspase-1 activation.10 Several chemically different molecules
have been shown to activate NLRP3 (ie, signal 2), including
extracellular ATP, monosodium urate crystals, and recently,
cholesterol crystals.11–13
Recent studies have suggested a role for NLRP3 inflam-
masome in atherosclerosis, although the results are
somewhat conflicting. Duewell and colleagues showed that
NLRP3-deficient bone marrow cells transplanted into
atherosclerosis-prone low-density lipoprotein receptor–defi-
cient mice had reduced atherosclerosis, and that cholesterol
crystals promoted IL-1b release from macrophages via
activation of the NLRP3 inflammasome.14 Furthermore,
NLRP3 inflammasome activation in cardiac fibroblasts was
found to enhance the severity of myocardial ischemia injury,15
and isolated hearts from NLRP3-deficient mice show atten-
uated ischemia–reperfusion injury.16 There is also substantial
evidence that activation of the NLRP3 inflammasome
enhances lipid deposition and migration of macrophages,
accelerating foam cell formation.17 However, others suggest
that progression of atherosclerosis is independent of inflam-
masome activation. Menu and coworkers created double
knock-out mice for apolipoprotein E (Apoe) and the NLRP3
inflammasome components NLRP3, Asc, and caspase-1, but
could not identify any difference between Apoe mice and the
different double knock-out genotypes regarding progression,
cell infiltration, phenotype, or stability of the atherosclerotic
plaque.18 Of note, the literature is virtually devoid of data on
NLRP3 expression in human atherosclerosis.
Mutations in the NLRP3 gene, resulting in hyperproduction
of IL-1b, have been associated with rare, hereditary, multisys-
tem inflammatory diseases, such as cryopyrin-associated
periodic syndromes.19 Polymorphisms in the NLRP3 gene
were also found to be associated with several common,
polygenic, inflammatory disorders including celiac disease,
abdominal aortic aneurysms, rheumatoid arthritis, and Crohn’s
disease.20–23 Villani and coworkers identified several additional
polymorphisms downstream of the NLRP3 gene that were
associated with risk of Crohn’s disease.24 Except for an
association with abdominal aortic aneurysms,21 there is little
data on associations between NLRP3 downstream regulatory
region polymorphisms and atherosclerotic disorders.
To elucidate the role of the NLRP3 inflammasome in human
atherosclerotic disease, we (1) examined the expression and
activation of the NLRP3 inflammasome in human atheroscle-
rotic carotid plaques, and (2) assessed 4 SNPs, rs4353135,
rs4266924, rs6672995, and rs10733113, located within the
downstream regulatory region of the NLRP3 gene for associ-
ation with the occurrence of MI and expression of NLRP3 and
inflammatory markers.
Methods
Study Subjects
(1) Gene expression patterns of NLRP3-related genes were
analyzed in the Biobank of Karolinska Endarterectomies (BiKE)
study at Centre for Molecular Medicine (CMM), Karolinska
Institute, Stockholm, Sweden.25 Carotid artery plaque tissues,
obtained during endarterectomy surgery from106 patientswith
ischemic cerebrovascular disease, were used to isolate mRNA.
Nonatherosclerotic vessels were obtained from iliac arteries
(n=9) and from intima of aorta (n=1) from transplant donors. (2)
Peripheral blood mononuclear cells (PBMCs) were collected
(n=98) as previously described.26 (3) Cytokine levels were
measured in the sera available from the Stockholm Coronary
Atherosclerosis Risk Factor (SCARF) cohort, which includes
387 MI patients and 387 controls. (4) The First-ever myocardial
Infarction study in AC-county (FIA) cohort from northern
Sweden, including 1016 controls and 555 MI patients,
was genotyped. Information regarding the MI definition,
sampling, and baseline characteristics of BiKE, SCARF, and
FIA cohorts has been previously reported.26–28 Ethical approval
was granted for each cohort from ethical review boards,
the studywas ethically performed according to the guidelines of
theHelsinki Declaration, and consent was given by the patients.
Immunohistochemistry
Sections of paraffin-embedded carotid plaque (n=3), collected
during endarterectomy surgery, were obtained from the BiKE.
Reagents for immunohistochemistry were from Biocare Med-
ical (Concord, CA). The 5-lm paraffin sections were treated
with Tissue Clear for deparaffinization and rehydrated in
graded ethanol (99.9–70%). The slides were subjected to
antigen retrieval by boiling in DIVA buffer and TE buffer. After
blocking with background Sniper, the primary antibodies
against NLRP3 (HPA012878; Sigma-Aldrich, St. Louis, MO;
1:50), ASC (ADI905173100; Enzo Life Sciences, Farmingdale,
NY; 1:200), CD68 (NCL-L-CD68, Novacastra, Newcastle, UK;
1:50), and smooth muscle actin (SMA; M0851; Dako,
Glostrup, Denmark; 1:500) were diluted in Da Vinci Green
solution and the slides were incubated with the primary
antibody for 1 hour at room temperature. Rabbit and mouse
IgG were used as negative control. A double-stain polymer
detection kit with alkaline phosphatase and horseradish
peroxidase was used to detect NLRP3 and ASC using Warp
Red and Vina green to detect CD68 and SMA. The sections
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were counterstained with hematoxylin QS (Vector Laborato-
ries, Burlingame, CA), dehydrated, and mounted in Pertex
(Histolab, G€oteborg, Sweden). Images were taken using a
Nikon OPTIPHOT-2 microscope and NIS-Element software.
Culturing of Atherosclerotic Carotid Plaques
Biopsies from atherosclerotic carotid plaques (n=9), obtained
from patients within 1 month of symptoms (Department of
Neurology, Oslo University Hospital Rikshospitalet, Oslo, Nor-
way)were rinsed in PBS and placed inDMEM/F12 (Gibco, Grand
Island, NY) enriched with 30 mg/mL endotoxin-free and fatty
acid–free BSA (Sigma, St. Louis, MO) within 4 hours of surgery,
and pre-incubatedwith orwithout lipopolysaccharide (LPS) from
Escherichia coli 026:B6 (Sigma, 100 ng/mL) as described.5,29
Before collection, the atherosclerotic area was carefully eval-
uated. The large section of the samples was segmented into
equal pieces macroscopically and was used in the experiments
to further minimize the problem with sampling error. After
18 hours, 3 mmol/L ATP (Sigma), 500 lg/mL cholesterol
crystals,30 or vehicle was added, and the tissue slices were
further incubated for 6 hours before tissue and conditioned
media were chilled on ice and harvested before being stored at
80°C. Protein levels of IL-1b in ex vivo stimulated carotid
plaque supernatants were measured by enzyme immunoassays
from R&D Systems Inc (Minneapolis, MN).
Expression of NLRP3-Related Components in
Human Atherosclerotic Lesions and Normal
Arteries; Role of NLRP3 Variants
Affymetrix HG-U133 plus 2.0 Gene chip arrays were used to
assess the expression of NLRP3, ASC, CASP1, IL1B, and IL18
mRNA in the samples from the BiKE study. In brief, RNA
purified using a Qiagen RNeasy kit was hybridized to arrays at
Karolinska Institute Affymetrix core facility and the RMA
procedure was used for normalization of the raw data.26 For
expression of quantitative trait loci (eQTL) analysis, the SNPs
were genotyped and association analysis was carried out as
previously described.25
Genotyping
Genotyping was carried out using a Taqman SNP genotype
assay and the 7900 HT Fast Realtime polymerase chain
reaction system (Applied Biosystems, Foster City, CA). The
polymerase chain reaction contained 10 ng of genomic DNA in
10 lL of master mix containing 2X Taqman genotyping Master
mix (Applied Biosystems) and 40X Taqman SNP Genotyping
Assay with predesigned primer and probes C__26052013,
C__28967719, C__28967716, C__30713847 for the SNPs
rs4353135, rs4266924, rs6672995, and rs10733113,
respectively. Genotyping accuracy was verified by repeating
the polymerase chain reaction in 10% randomly selected
samples.
Inflammatory Markers in Plasma
Inflammatory cytokines were measured in plasma from SCARF.
IL-18 levels were measured using an ELISA kit from R&D
Systems Inc. (Minneapolis, MN) as previously described.31
Concentrations of IL-1b, tumor necrosis factor-a, and mono-
cyte chemoattractant peptide (MCP-1/CCL2) were analyzed
using an Evidence automated biochip array system (Randox
Laboratories Ltd., Co Antrim, UK).32 The levels of high-
sensitivity C-reactive protein were measured in SCARF and
FIA as reported by Samnegard et al28 and Wennberg et al,33
respectively.
Statistical Analysis
A 2-tailed Student t test was used for analyzing mRNA levels of
NLRP3, ASC, CASP1, IL1B, and IL18 between carotid lesions and
transplant donor vessels, respectively. The carotid lesions
consisted of the 106 patients described from the BiKE cohort.
The transplant donor vessels consisted of nonatherosclerotic
vessels as similarly described. Both tested groupswere normally
distributed according to a Shapiro–Wilks test (P>0.1). The
Mann–Whitney U-test was used for analyzing the ex vivo
experiments of carotid plaques. STATISTICA 7.1 software
(StatSoft) was used for the statistical analysis of cytokine
profiling. Assessment of association between NLRP3 mRNA
expression and genotypes in different tissues was performed
using an additive linear regression model as previously men-
tioned.25 Investigation of possible associations between cytoki-
nes and genotyped SNPs was performed using linear regression
with an additive genetic model and adjusted for age, sex, and
presence of MI in PLINK.34 Association between SNPs and MI
was analyzed with the v2 test using the SPSS software package
(SPSS, Inc, Chicago, IL) and EpiInfo software 2008 (Centre for
Disease Control and Prevention, Atlanta, GA). Since the analysis
was solely directed at the NLRP3 gene-testing hypotheses, the
significance level was here considered to be P<0.05.
Results
Increased NLRP3, ASC, caspase-1, IL-1b, and IL-18
mRNA Expression in Human Carotid Artery
Plaques
The mRNA levels of NLRP3 inflammasome components
were compared between atherosclerotic (n=106) and
nonatherosclerotic (n=10) arteries. The expression of NLRP3,
ASC, CASP1, IL1B, and IL18 mRNA was found to be markedly
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increased in atherosclerotic as compared to nonatherosclerotic
vessels (P<0.0001 for all comparisons; Figure 1A through 1E),
indicating upregulation in the atherosclerotic lesion of tran-
scripts for NLRP3 inflammasome components. Within carotid
plaques, mRNA levels of NLRP3, but not of ASC, CASP1, IL1B,
and IL18 (Figure S1), were significantly increased in patients
with symptomatic (n=85) compared to patients with asymp-
tomatic lesions (n=40, P<0.05) (Figure 1F). Levels of NLRP3
mRNA also showed a correlation with mRNA levels of the
macrophage marker CD68 (r=0.66, P<0.001, data not shown).
NLRP3 Immunoreactivity in Carotid Plaque
Immunostaining for NLRP3 or ASC was performed in carotid
plaques (n=3). In line with the correlation between NLRP3 and
the macrophage marker CD68, CD68-positive macrophages
were expressed in the same areas as NLRP3. In addition, ASC
was found to be expressed by CD68-positive macrophages in
plaque. Also, NLRP3 and ASC staining was occasionally
expressed in smooth muscle cells (SMC) of atherosclerotic
lesions (Figure 2).
LPS and Cholesterol Crystals Induce IL-1b
Release in Human Carotid Plaque
To further assess the relevance of NLRP3 inflammasome in
the atherosclerotic arteries, we examined the induction of
IL-1b protein release from freshly isolated human carotid
plaques by using TLR4 activation (ie, LPS) as signal 1 and
ATP or cholesterol crystals as signal 2. As shown in
Figure 1. Expression of (A) NLR family, pyrin domain containing 3 (NLRP3) (P<0.00001); (B) Apoptosis-
associated speck-like protein containing a CARD (ASC) (P<0.00000001); (C) Caspase-1 (P<0.000001); (D)
Interleukin (IL)-1b (P<0.0000000000001), and (E) IL-18 (P<0.00000000001) mRNA in human atheroscle-
rotic carotid lesions compared to transplant donor vessels from the Biobank of Karolinska Endarterec-
tomies (BiKE) cohort. F, NLRP3 mRNA expression in asymptomatic plaques compared to symptomatic
plaques from the BiKE cohort (P<0.035).
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Figure 3A, LPS, ATP, and particularly the combination of
these 2 stimuli markedly enhanced the release of IL-1b.
Notably, a similar pattern was also seen when cholesterol
crystals were used in combination with LPS, with signifi-
cantly increased release of IL-1b. (Figure 3A and 3B).
However, ATP was found to be more potent than cholesterol
crystal stimulation. These findings demonstrate that
atherosclerotic carotid plaques contain NLRP3 inflamma-
somes that could be activated when exposed to TLR4
activation and ATP or cholesterol crystals. Importantly, even
without addition of LPS, there was significant release of IL-
1b upon stimulation with ATP or cholesterol crystals,
Figure 2. Immunohistochemical staining of NLR family, pyrin domain containing 3 (NLRP3), Apoptosis-
associated speck-like protein containing a CARD (ASC), CD68 and smooth muscle actin (SMA) in carotid
plaque. Lower panels show the magnified image. Left panels show the immunostaining of NLRP3/ASC (red)
and CD68 (green). Right panels show immunostaining of NLRP3/ASC (red) and SMA (green). Arrows
indicate co-localization of NLRP3 or ASC in CD68- (left) or SMA-positive cells (right). The scale bars for
91.25 and 940 objectives are 1 mm and 100 lm, respectively.
DOI: 10.1161/JAHA.115.003031 Journal of the American Heart Association 5
NLRP3 in Cardiovascular Disease Varghese et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on M
ay 15, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
suggesting that plaques were already primed for inflamma-
some activation.
Association Between Genetic Variants and NLRP3
mRNA Level in Plaque and PBMC
To examine cis-acting regulatory effects of the variants on the
NLRP3 gene, we investigated the associations between geno-
type and gene expression in atherosclerotic plaque (BiKE
population, n=106) and PBMC (healthy controls, n=98). The
polymorphisms rs6672995 (P=0.002) and rs10733113
(P=0.008) exhibited significant association with NLRP3 expres-
sion in PBMCs, but no significant association in PBMCs were
evident for rs4353135 or rs4266924 (P=0.30 and 0.15,
respectively; Figure 4). In plaque, a trend of moderate associ-
ation was found between NLRP3 expression and rs4266924
(P=0.06), but no significant association was evident between
NLRP3 expression and rs6672995, rs10733113, or rs4353135
in plaque (P=0.08, 0.13 and 0.19, respectively, Figure 4).
Association Between NLRP3 Variants and
Cytokines Levels in Plasma
As NLRP3 is involved in IL-1b processing, we next examined
the influence of these NLRP3 variants on IL-1b levels in the
SCARF cohort. We found that the minor allele of rs4266924
and rs10733113 was significantly associated with increased
IL-1b levels in controls (P=0.03 and 0.02, respectively), but
not in MI patients (P=0.29, P=0.15; Table 1). No association
was found between these variants and IL-18, tumor necrosis
factor-a, MCP-1, or C-reactive protein levels in either patients
or controls (data not shown).
Association Between the NLRP3 Polymorphisms
and MI
Next, we genotyped 555 MI patients and 1016 healthy
controls in the FIA cohort for the SNPs rs4353135,
rs4266924, rs6672995, and rs10733113 in the downstream
regulatory region of NLRP3 gene.24 Approximately 1.2% of the
samples were excluded due to poor genotype calling. The
SNPs showed no significant deviation from the Hardy–
Weinberg equilibrium, in the case or control group. No overall
significant association was observed between the variants
and MI; however, the heterozygous genotype of rs4353135
showed a trend toward the higher risk of MI (P=0.06; Table 2).
Discussion
Despite evidence of NLRP3 inflammasome activation in
experimental atherosclerosis, neither the functional profile
of activated NLRP3 inflammasome in the human plaque nor
the association between NLRP3 genotype and plaque expres-
sion are known. In this study, we show that the mRNA level of
NLRP3 inflammasome-related genes is significantly increased
in human atherosclerotic plaques compared to nonatheroscle-
rotic vessels, and for NLRP3, particularly high expression was
seen in those with symptomatic lesions. Previously, Zheng
et al have shown enhanced expression of NLRP3 in
atherosclerotic aorta as compared with control samples.35
In the present study, we extend these previous findings in
several ways. First, while Zheng et al examined samples from
36 patients, the present study include samples from 106
patients. Second, in addition to immunohistochemistry, we
also performed mRNA analysis, which is a quantitatively more
accurate method. Third, the transcripts of the other NLRP3
inflammasome components (ie, ASC, caspase-1, IL-1b, and
IL-18) were also analyzed and the pathophysiological rele-
vance of NLRP3 inflammasome in human atherosclerotic
lesions was assessed in the cultured biopsies. However, the
validation of our results based on microarray without real-time
polymerase chain reaction verification might be a limitation to
Figure 3. A, IL-1b release from human carotid plaque (n=9)
subjected to lipopolysaccharide (LPS) (113.8138.6 pg/mL),
ATP (78129.0 pg/mL), or LPS+ATP (413.8412.7 pg/mL)
treatment and in control (912.7 pg/mL). B, IL-1b release from
human carotid plaque (n=7) subjected to LPS (145.8112.7 pg/
mL), cholesterol crystal (38.38.3 pg/mL), or LPS+ cholesterol
crystal (351.1206.4 pg/mL) treatment and in control (15.2 pg/
mL). #P<0.05 vs LPS. **P<0.005 vs unstim. ***P<0.001 vs
unstim.
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our study, although microarray analysis is considered a more
appropriate method for complex tissue and therefore is
preferred.36
In the lesions, NLRP3 and ASC co-localized with macro-
phages and SMC. Moreover, our ex vivo experiments suggest
that NLRP3 inflammasome generates significant amounts of
Figure 4. Association between genotype of variants and expression level of the NLR family, pyrin
domain containing 3 (NLRP3) gene in plaque and peripheral blood mononuclear cells (PBMCs). The Y axis
represents log10 (P), calculated using additive model for the association between genotype and
expression level. The X axis represents different genotypes of the variants. The minimum and maximum
values are represented by whiskers, the first and third quartiles (box), the median values (medlines),
outliers are displayed as circles. The Y axis represents the mRNA expression level of NLRP3.
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mature IL-1b in the plaque. This was not only observed upon
LPS/ATP stimulation. LPS/cholesterol crystal activation also
produced IL-1b, and even the addition of ATP or cholesterol
crystals alone resulted in increased IL-1b secretion, which
suggests that the cells in the plaque were already primed for
inflammasome activation. Moreover, SNP analyses revealed
associations between certain gene variants and increased
NLRP3 in PBMCs and IL-1b levels in plasma. Our findings
support a role for NLRP3 inflammasome in human atheroscle-
rosis, linking cholesterol accumulation and inflammation
within the atherosclerotic lesion.
The upregulated levels of NLRP3, ASC, caspase-1, IL-1b,
and IL-18 mRNA in the atherosclerotic plaque can be
implicated as a checkpoint for NLRP3 inflammasome activa-
tion,37 suggesting the likelihood of activation of this inflam-
masome in the human atherosclerotic lesion. We also
investigated the expression of NLRP3 in relation to plaque
vulnerability and found the NLRP3 expression to be signifi-
cantly increased in patients with symptomatic plaques when
compared to patients with asymptomatic lesions, which is in
agreement with the results from Zheng et al, who reported a
significant correlation between aortic NLRP3 expression and
Gensini coronary severity scores.35 Enhanced expression of
NLRP3 in the symptomatic plaques indicates high-grade
inflammation that might be due to cholesterol crystallization
in the lipid-rich necrotic core and the presence of inflamma-
tory cell infiltrates often observed in high-grade carotid
stenosis.14,38 The mRNA levels of NLRP3 were significantly
correlated with mRNA levels of CD68, and CD68-positive
macrophages were expressed in the same areas of
atherosclerotic lesions as NLRP3 and ASC. In agreement
with our results, Peng et al showed the expression of NLRP3
in the human atherosclerotic areas with CD68-positive
macrophage accumulation.39 Moreover, the expression of
NLRP3 in SMC in the intima of atherosclerotic lesions may
reflect the role of SMC in IL-1b production, which is in line
with our previous studies showing that SMC express NLRP3
and produce IL-1b.40 Infiltrating macrophages have been
linked to plaque progression and destabilization of high-grade
carotid stenosis,41 and our findings in the present study
suggest that this may involve activation of NLRP3 inflamma-
some within these cells.
As NLRP3 is involved in IL-1b processing, we also analyzed
IL-1b release after stimulating the atherosclerotic plaque with
diverse agents such as LPS, extracellular ATP, and cholesterol
crystals. Cholesterol crystals, as well as ATP, have previously
been shown to activate NLRP3 inflammasome, thereby
inducing the release of IL-1b in LPS-primed PBMCs.14,42 In
our previous studies we have shown that LPS-stimulated
carotid lesions release IL-1b.5 In the present study, we extend
these findings by showing that human carotid plaques not
only contain NLRP3 inflammasome, but also release IL-1b
upon TLR4 activation and exposure to ATP or cholesterol
crystals. The finding that cholesterol crystals can activate IL-
1b release from plaques in the absence of a TLR4 priming
agent suggests that the cells have already received a priming
signal for NLRP3 activation. This may reflect in situ priming of
the inflammasome, which is consistent with our mRNA data.
The effect of ATP was found to be more pronounced in
comparison with cholesterol crystals, especially when these
stimuli were combined with LPS. These findings may possibly
depend on different mechanisms of signaling/uptake or, more
simply, increased accessibility of ATP compared to cholesterol
crystals due to different molecular size in our ex vivo
experiments. However, whereas release of extracellular ATP
may be relevant during plaque destabilization with increased
cell death within the lesion, the exposure of cholesterol
crystals known to be present in atherosclerotic lesions may
be more relevant during the chronic atherosclerotic process.
Our data along with other studies indicate that human
atherosclerotic lesions contain NLRP3 inflammasomes that
are activated and release IL-1b when exposed to TLR4
activation and ATP or cholesterol crystals. The release of IL-
1b performs a key role in the recruitment of neutrophils,
thereby promoting an inflammatory milieu in the atheroscle-
rotic plaque.
We also investigated the genetic association between the
genotypes of SNPs in the NLRP3 downstream region and
NLRP3 gene expression. The minor alleles of rs4353135,
rs4266924, rs6672995, and rs10733113 within the NLRP3
downstream regulatory region were previously found to be
associated with risk of the development of Crohn’s disease.24
In the present study, we found that the polymorphisms
rs6672995 and rs10733113 were significantly associated
with elevated NLRP3 expression in PBMCs of healthy controls
Table 1. Association of SNPs With IL-1b Level in Plasma
From Controls and Patients With MI of the SCARF Cohort
Using ELISA
SNP Samples Beta SEM P Value
Controls
rs4353135 157 2.7 3.01 0.37
rs4266924 160 2.29 4.26 0.03
rs6672995 154 5.74 3.84 0.13
rs10733113 153 1.27 0.56 0.02
MI patients
rs4353135 167 1.80 1.28 0.16
rs4266924 177 1.63 1.56 0.29
rs6672995 171 2.12 1.28 0.09
rs10733113 166 2.06 1.44 0.15
Beta indicates the magnitude of effect per allele; MI, Myocardial Infarction; SCARF,
Stockholm Coronary Atherosclerosis Risk Factor; SNPs, single nucleotide polymorphisms.
DOI: 10.1161/JAHA.115.003031 Journal of the American Heart Association 8
NLRP3 in Cardiovascular Disease Varghese et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on M
ay 15, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
and a borderline significant association of rs4266924 was
evident in plaque. We also found that the expression of IL-1b
was significantly associated with the polymorphisms
rs4266924 and rs10733113 in healthy controls. However,
no significant association was evident for the polymorphisms
investigated and IL-1b in plasma from MI patients. This is
partly in agreement with Villani and coworkers, who showed a
significant association between these variants, NLRP3 expres-
sion, and IL-1b production.24 The association of SNPs with
increased plasma IL-1b cytokine in the control group may
suggest a role of the SNPs in the regulation of the expression
of NLRP3 and IL-1b in healthy individuals. The lack of
association in the plaque of MI patients may suggest that
several other factors expressed during the disease may
overdominate the effect of these SNPs.
In the present study, we also examined the association of
SNPs rs4353135, rs4266924, rs6672995, and rs10733113
with the risk of MI in the FIA cohort. Although no significant
association was found between the variants and MI, the
heterozygous genotype of rs4353135 showed a trend toward
higher risk. Our results are in agreement with previous
studies on the absence of genetic association between the
Table 2. Overview of the Genotype and Allele Frequencies of NLRP3 Downstream Single Nucleotide Polymorphisms (SNPs) in
Patients With Myocardial Infarction and Healthy Controls in the FIA Cohort
SNP Genotype Patients Controls Odds Ratio (95% CI) P Value
Genotype frequencies
rs4353135 n=459 (%) n=860 (%)
TT 237 (52) 483 (56) 1
GG 29 (6) 63 (7) 0.93 (0.58–1.49) 0.78
GT 193 (42) 31 (37) 1.25 (0.98–1.58) 0.06
rs4266924 n=490 (%) n=902 (%)
AA 380 (78) 708 (79) 1
GG 4 (0.8) 10 (0.1) 1.3 (0.42–4.36) 0.61
AG 106 (21) 184 (21) 1.4 (0.44–4.70) 0.54
rs6672995 n=491 (%) n=901 (%)
GG 355 (72) 640 (71) 1
AA 13 (3) 23 (3) 1.0 (0.51–2.03) 0.95
AG 123 (25) 238 (26) 0.93 (0.72–1.20) 0.58
rs10733113 n=432 (%) n=802 (%)
GG 320 (74) 592 (74) 1
AA 6 (1) 12 (1) 0.92 (0.34–2.48) 0.87
AG 106 (25) 198 (25) 0.99 (0.75–1.30) 0.94
Allele frequencies
rs4353135 n=918 (%) n=1720 (%)
T 667 (73) 1280 (74) 1
G 251 (27) 440 (26) 1.0 (0.91–1.3) 0.32
rs4266924 n=980 (%) n=1804 (%)
A 866 (88) 1600 (89) 1
G 114 (12) 204 (11) 0.9 (0.7–1.23) 0.79
rs6672995 n=982 (%) n=1802 (%)
G 833 (85) 1518 (84) 1
A 149 (15) 284 (16) 0.95 (0.7–1.18) 0.68
rs10733113 n=864 (%) n=1604 (%)
G 746 (86) 1382 (86) 1
A 118 (14) 222 (14) 0.9 (0.7–1.25) 0.89
FIA indicates First-ever myocardial Infarction study in Ac-county; NLRP3, NLR Family, Pyrin Domain Containing 3; SNPs, Single Nucleotide Polymorphisms.
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above SNPs in Crohn’s disease and ankylosing spondyli-
tis.43,44 The fact that the present study contains a relatively
low number of individuals might be a limitation of the study,
but we were able to reach statistical power of 78% for
rs4353135 (assuming an effect of 1.21) and >95% of power
for the additional 3 SNPs to detect an effect (assuming
effects of 1.69, 1.53, and 1.78 for rs4266924, rs6672995,
and rs10733113, respectively) and minor allele frequency
based on publicly available information at dbSNP by NCBI for
a European population.24 In particular, the absence of
association between the NLRP3 variants and MI in a northern
Swedish population should be interpreted cautiously due to
the small sample size and the interaction of these loci with
environmental exposures. Furthermore, the FIA cohort origins
from a region where genetic drift has been proposed, which
may explain a possible divergence from other cohorts.45 On
the other hand, a strength of the present study is the use of 2
demographically different Swedish cohorts (FIA and SCARF)
for the association studies with the combination of a third
cohort of plaque (BiKE), since atherosclerosis is a frequent
underlying disease for MI. However, ideally it would have
been better to perform all analyses on all study subjects, but
due to different study design of the different cohorts, this was
not an option and is therefore a limitation to the study.
In conclusion, the present study shows that NLRP3
inflammasome-related genes are highly expressed in
atherosclerotic plaque and sensitive to activation when
exposed to TLR4 activation and ATP or cholesterol crystals.
Although we lack more quantitative protein data (eg, Western
blot) and co-localization of NLRP3 to cholesterol crystals and
foam cells, our results suggest the possible role of NLRP3 and
its variants in accelerating atherosclerosis.
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SUPPLEMENTAL MATERIAL 
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 Figure S1.  A) Caspase-1 (CASP1; P=0.0981); B) Interleukin (IL) 1B (P=0.834); C) IL18 
(P=0.259) and D) Apoptosis-associated speck like protein containing a CARD (PYCARD/ASC; 
P= 0.0842) mRNA expression in asymptomatic plaques compared to symptomatic plaques.  
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